Despite recent advances, cancer remains the leading cause of death in France with~150,000 annual deaths (INCA, 2012). Notably, lung cancer is one of the most aggressive, with 29 100 deaths in 2011. The five-year survival is only 10 % of patients with lung cancer non-small cell (NSCLC, 80% of lung cancers), so it's a medical/scientific...
-
December 20, 2013 (v1)PublicationUploaded on: December 3, 2022
-
September 30, 2015 (v1)Journal article
Survival rates of patients with metastatic or recurrent cancers have remained virtually unchanged during the past 30 years. This fact makes the need for new therapeutic options even more urgent. An attractive option would be to target autophagy, an essential quality control process that degrades toxic aggregates, damaged organelles, and...
Uploaded on: December 4, 2022 -
May 1, 2011 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
August 20, 2015 (v1)Journal article
Metastatic renal cell carcinomas (mRCC) are highly vascularized tumors that are a paradigm for the treatment with antiangiogenesis drugs targeting the vascular endothelial growth factor (VEGF) pathway. The available drugs increase the time to progression but are not curative and the patients eventually relapse. In this study we have focused our...
Uploaded on: December 4, 2022 -
February 28, 2017 (v1)Journal article
The eukaryotic initiation factor 5A (eIF5A), which is highly conserved throughout evolution, has the unique characteristic of post-translational activation through hypusination. This modification is catalyzed by two enzymatic steps involving deoxyhypusine synthase (DHPS) and deoxyhypusine hydroxylase (DOHH). Notably, eIF5A may be involved in...
Uploaded on: December 4, 2022